vs
Side-by-side financial comparison of Nutex Health, Inc. (NUTX) and Tecnoglass Inc. (TGLS). Click either name above to swap in a different company.
Tecnoglass Inc. is the larger business by last-quarter revenue ($245.3M vs $151.7M, roughly 1.6× Nutex Health, Inc.). Tecnoglass Inc. runs the higher net margin — 10.6% vs 7.8%, a 2.8% gap on every dollar of revenue. On growth, Tecnoglass Inc. posted the faster year-over-year revenue change (2.4% vs -41.1%). Nutex Health, Inc. produced more free cash flow last quarter ($69.0M vs $11.4M). Over the past eight quarters, Nutex Health, Inc.'s revenue compounded faster (50.0% CAGR vs 12.8%).
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
Tecnoglass Inc. is a leading manufacturer of high-performance architectural glass, aluminum windows, doors, and associated building components. It primarily caters to residential and commercial construction sectors across North America and Latin America, offering custom, energy-efficient solutions for new construction and renovation projects.
NUTX vs TGLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $151.7M | $245.3M |
| Net Profit | $11.8M | $26.1M |
| Gross Margin | 30.4% | 40.0% |
| Operating Margin | 20.4% | 18.3% |
| Net Margin | 7.8% | 10.6% |
| Revenue YoY | -41.1% | 2.4% |
| Net Profit YoY | -80.8% | -44.5% |
| EPS (diluted) | $2.34 | $0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $151.7M | $245.3M | ||
| Q3 25 | $267.8M | $260.5M | ||
| Q2 25 | $244.0M | $255.5M | ||
| Q1 25 | $211.8M | $222.3M | ||
| Q4 24 | $257.6M | $239.6M | ||
| Q3 24 | $78.8M | $238.3M | ||
| Q2 24 | $76.1M | $219.7M | ||
| Q1 24 | $67.5M | $192.6M |
| Q4 25 | $11.8M | $26.1M | ||
| Q3 25 | $55.4M | $47.2M | ||
| Q2 25 | $-17.7M | $44.1M | ||
| Q1 25 | $21.2M | $42.2M | ||
| Q4 24 | $61.6M | $47.0M | ||
| Q3 24 | $-8.8M | $49.5M | ||
| Q2 24 | $-364.0K | $35.0M | ||
| Q1 24 | $-364.0K | $29.7M |
| Q4 25 | 30.4% | 40.0% | ||
| Q3 25 | 57.8% | 42.7% | ||
| Q2 25 | 51.2% | 44.7% | ||
| Q1 25 | 55.9% | 43.9% | ||
| Q4 24 | 55.0% | 44.5% | ||
| Q3 24 | 27.8% | 45.8% | ||
| Q2 24 | 29.7% | 40.8% | ||
| Q1 24 | 15.1% | 38.8% |
| Q4 25 | 20.4% | 18.3% | ||
| Q3 25 | 48.7% | 25.1% | ||
| Q2 25 | 13.8% | 24.0% | ||
| Q1 25 | 38.1% | 26.7% | ||
| Q4 24 | 44.4% | 28.0% | ||
| Q3 24 | 12.3% | 28.4% | ||
| Q2 24 | 7.0% | 23.3% | ||
| Q1 24 | 2.1% | 21.3% |
| Q4 25 | 7.8% | 10.6% | ||
| Q3 25 | 20.7% | 18.1% | ||
| Q2 25 | -7.3% | 17.3% | ||
| Q1 25 | 10.0% | 19.0% | ||
| Q4 24 | 23.9% | 19.6% | ||
| Q3 24 | -11.2% | 20.8% | ||
| Q2 24 | -0.5% | 15.9% | ||
| Q1 24 | -0.5% | 15.4% |
| Q4 25 | $2.34 | $0.57 | ||
| Q3 25 | $7.76 | $1.01 | ||
| Q2 25 | $-2.95 | $0.94 | ||
| Q1 25 | $3.33 | $0.90 | ||
| Q4 24 | $11.56 | $1.00 | ||
| Q3 24 | $-1.72 | $1.05 | ||
| Q2 24 | $-0.07 | $0.75 | ||
| Q1 24 | $-0.08 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $185.6M | $104.1M |
| Total DebtLower is stronger | — | $174.4M |
| Stockholders' EquityBook value | $329.4M | $713.1M |
| Total Assets | $918.5M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $185.6M | $104.1M | ||
| Q3 25 | $166.0M | $127.1M | ||
| Q2 25 | $96.7M | $140.9M | ||
| Q1 25 | $84.7M | $160.2M | ||
| Q4 24 | $40.6M | $137.5M | ||
| Q3 24 | $46.9M | $124.8M | ||
| Q2 24 | $40.8M | $129.5M | ||
| Q1 24 | $30.0M | $138.8M |
| Q4 25 | — | $174.4M | ||
| Q3 25 | — | $114.7M | ||
| Q2 25 | — | $110.6M | ||
| Q1 25 | — | $110.6M | ||
| Q4 24 | — | $111.1M | ||
| Q3 24 | — | $126.8M | ||
| Q2 24 | — | $144.7M | ||
| Q1 24 | — | $160.9M |
| Q4 25 | $329.4M | $713.1M | ||
| Q3 25 | $317.2M | $764.0M | ||
| Q2 25 | $235.3M | $736.0M | ||
| Q1 25 | $176.9M | $685.1M | ||
| Q4 24 | $132.4M | $631.2M | ||
| Q3 24 | $60.4M | $613.3M | ||
| Q2 24 | $62.7M | $574.8M | ||
| Q1 24 | $63.0M | $573.6M |
| Q4 25 | $918.5M | $1.3B | ||
| Q3 25 | $964.5M | $1.2B | ||
| Q2 25 | $841.0M | $1.2B | ||
| Q1 25 | $761.9M | $1.1B | ||
| Q4 24 | $655.3M | $1.0B | ||
| Q3 24 | $438.5M | $996.3M | ||
| Q2 24 | $422.4M | $942.5M | ||
| Q1 24 | $404.3M | $981.6M |
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.25× | ||
| Q1 24 | — | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $70.4M | $31.0M |
| Free Cash FlowOCF − Capex | $69.0M | $11.4M |
| FCF MarginFCF / Revenue | 45.5% | 4.7% |
| Capex IntensityCapex / Revenue | 0.9% | 8.0% |
| Cash ConversionOCF / Net Profit | 5.95× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | $245.6M | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $70.4M | $31.0M | ||
| Q3 25 | $99.5M | $40.0M | ||
| Q2 25 | $27.3M | $17.9M | ||
| Q1 25 | $51.0M | $46.9M | ||
| Q4 24 | $54.0K | $61.1M | ||
| Q3 24 | $6.8M | $41.5M | ||
| Q2 24 | $13.3M | $34.5M | ||
| Q1 24 | $3.1M | $33.4M |
| Q4 25 | $69.0M | $11.4M | ||
| Q3 25 | $99.2M | $21.2M | ||
| Q2 25 | $26.5M | $-14.7M | ||
| Q1 25 | $50.9M | $16.5M | ||
| Q4 24 | $-341.0K | $35.4M | ||
| Q3 24 | $6.2M | $17.8M | ||
| Q2 24 | $12.7M | $14.2M | ||
| Q1 24 | $2.3M | $23.6M |
| Q4 25 | 45.5% | 4.7% | ||
| Q3 25 | 37.0% | 8.2% | ||
| Q2 25 | 10.9% | -5.7% | ||
| Q1 25 | 24.0% | 7.4% | ||
| Q4 24 | -0.1% | 14.8% | ||
| Q3 24 | 7.8% | 7.5% | ||
| Q2 24 | 16.7% | 6.5% | ||
| Q1 24 | 3.4% | 12.2% |
| Q4 25 | 0.9% | 8.0% | ||
| Q3 25 | 0.1% | 7.2% | ||
| Q2 25 | 0.3% | 12.7% | ||
| Q1 25 | 0.0% | 13.7% | ||
| Q4 24 | 0.2% | 10.7% | ||
| Q3 24 | 0.8% | 9.9% | ||
| Q2 24 | 0.7% | 9.2% | ||
| Q1 24 | 1.1% | 5.1% |
| Q4 25 | 5.95× | 1.19× | ||
| Q3 25 | 1.80× | 0.85× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | 2.40× | 1.11× | ||
| Q4 24 | 0.00× | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | — | 1.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
